Suppr超能文献

小分子靶向“不可成药”转录因子的研究进展。

Advances in targeting 'undruggable' transcription factors with small molecules.

机构信息

David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.

The Broad Institute of MIT and Harvard, Cambridge, MA, USA.

出版信息

Nat Rev Drug Discov. 2021 Sep;20(9):669-688. doi: 10.1038/s41573-021-00199-0. Epub 2021 May 18.

Abstract

Transcription factors (TFs) represent key biological players in diseases including cancer, autoimmunity, diabetes and cardiovascular disease. However, outside nuclear receptors, TFs have traditionally been considered 'undruggable' by small-molecule ligands due to significant structural disorder and lack of defined small-molecule binding pockets. Renewed interest in the field has been ignited by significant progress in chemical biology approaches to ligand discovery and optimization, especially the advent of targeted protein degradation approaches, along with increasing appreciation of the critical role a limited number of collaborators play in the regulation of key TF effector genes. Here, we review current understanding of TF-mediated gene regulation, discuss successful targeting strategies and highlight ongoing challenges and emerging approaches to address them.

摘要

转录因子 (TFs) 是包括癌症、自身免疫、糖尿病和心血管疾病在内的多种疾病中的关键生物因子。然而,除了核受体之外,由于结构显著无序且缺乏明确的小分子结合口袋,转录因子一直被认为是小分子配体“不可成药”的靶点。化学生物学方法在配体发现和优化方面取得了显著进展,特别是靶向蛋白降解方法的出现,以及对少数关键 TF 效应基因调控因子的重要作用的认识不断提高,这重新激发了人们对该领域的兴趣。在这里,我们回顾了目前对 TF 介导的基因调控的理解,讨论了成功的靶向策略,并强调了当前面临的挑战和新兴的方法来解决这些问题。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验